Transformation of tenofovir into stable ProTide nanocrystals with long-acting pharmacokinetic profiles

Antiretroviral therapy (ART) for the treatment of HIV-1 requires life-long daily adherence to supress viral replication, and nucleoside reverse transcriptase inhibitors that are commonly used in ART have not been converted into long-acting agents. Here, the authors report two lipophilic tenofovir (T...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Denise A. Cobb, Nathan Smith, Suyash Deodhar, Aditya N. Bade, Nagsen Gautam, Bhagya Laxmi Dyavar Shetty, JoEllyn McMillan, Yazen Alnouti, Samuel M. Cohen, Howard E. Gendelman, Benson Edagwa
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/e78ef827a6654617b246aed85af2acee
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e78ef827a6654617b246aed85af2acee
record_format	dspace
spelling	oai:doaj.org-article:e78ef827a6654617b246aed85af2acee2021-12-02T18:02:32ZTransformation of tenofovir into stable ProTide nanocrystals with long-acting pharmacokinetic profiles10.1038/s41467-021-25690-52041-1723https://doaj.org/article/e78ef827a6654617b246aed85af2acee2021-09-01T00:00:00Zhttps://doi.org/10.1038/s41467-021-25690-5https://doaj.org/toc/2041-1723Antiretroviral therapy (ART) for the treatment of HIV-1 requires life-long daily adherence to supress viral replication, and nucleoside reverse transcriptase inhibitors that are commonly used in ART have not been converted into long-acting agents. Here, the authors report two lipophilic tenofovir (TVF) ProTide nanoformulations, NM1TFV and NM2TFV, which sustain drug levels above therapeutic concentrations for two months after a single intramuscular dose in rats.Denise A. CobbNathan SmithSuyash DeodharAditya N. BadeNagsen GautamBhagya Laxmi Dyavar ShettyJoEllyn McMillanYazen AlnoutiSamuel M. CohenHoward E. GendelmanBenson EdagwaNature PortfolioarticleScienceQENNature Communications, Vol 12, Iss 1, Pp 1-16 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Science Q
spellingShingle	Science Q Denise A. Cobb Nathan Smith Suyash Deodhar Aditya N. Bade Nagsen Gautam Bhagya Laxmi Dyavar Shetty JoEllyn McMillan Yazen Alnouti Samuel M. Cohen Howard E. Gendelman Benson Edagwa Transformation of tenofovir into stable ProTide nanocrystals with long-acting pharmacokinetic profiles
description	Antiretroviral therapy (ART) for the treatment of HIV-1 requires life-long daily adherence to supress viral replication, and nucleoside reverse transcriptase inhibitors that are commonly used in ART have not been converted into long-acting agents. Here, the authors report two lipophilic tenofovir (TVF) ProTide nanoformulations, NM1TFV and NM2TFV, which sustain drug levels above therapeutic concentrations for two months after a single intramuscular dose in rats.
format	article
author	Denise A. Cobb Nathan Smith Suyash Deodhar Aditya N. Bade Nagsen Gautam Bhagya Laxmi Dyavar Shetty JoEllyn McMillan Yazen Alnouti Samuel M. Cohen Howard E. Gendelman Benson Edagwa
author_facet	Denise A. Cobb Nathan Smith Suyash Deodhar Aditya N. Bade Nagsen Gautam Bhagya Laxmi Dyavar Shetty JoEllyn McMillan Yazen Alnouti Samuel M. Cohen Howard E. Gendelman Benson Edagwa
author_sort	Denise A. Cobb
title	Transformation of tenofovir into stable ProTide nanocrystals with long-acting pharmacokinetic profiles
title_short	Transformation of tenofovir into stable ProTide nanocrystals with long-acting pharmacokinetic profiles
title_full	Transformation of tenofovir into stable ProTide nanocrystals with long-acting pharmacokinetic profiles
title_fullStr	Transformation of tenofovir into stable ProTide nanocrystals with long-acting pharmacokinetic profiles
title_full_unstemmed	Transformation of tenofovir into stable ProTide nanocrystals with long-acting pharmacokinetic profiles
title_sort	transformation of tenofovir into stable protide nanocrystals with long-acting pharmacokinetic profiles
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/e78ef827a6654617b246aed85af2acee
work_keys_str_mv	AT deniseacobb transformationoftenofovirintostableprotidenanocrystalswithlongactingpharmacokineticprofiles AT nathansmith transformationoftenofovirintostableprotidenanocrystalswithlongactingpharmacokineticprofiles AT suyashdeodhar transformationoftenofovirintostableprotidenanocrystalswithlongactingpharmacokineticprofiles AT adityanbade transformationoftenofovirintostableprotidenanocrystalswithlongactingpharmacokineticprofiles AT nagsengautam transformationoftenofovirintostableprotidenanocrystalswithlongactingpharmacokineticprofiles AT bhagyalaxmidyavarshetty transformationoftenofovirintostableprotidenanocrystalswithlongactingpharmacokineticprofiles AT joellynmcmillan transformationoftenofovirintostableprotidenanocrystalswithlongactingpharmacokineticprofiles AT yazenalnouti transformationoftenofovirintostableprotidenanocrystalswithlongactingpharmacokineticprofiles AT samuelmcohen transformationoftenofovirintostableprotidenanocrystalswithlongactingpharmacokineticprofiles AT howardegendelman transformationoftenofovirintostableprotidenanocrystalswithlongactingpharmacokineticprofiles AT bensonedagwa transformationoftenofovirintostableprotidenanocrystalswithlongactingpharmacokineticprofiles
_version_	1718378901090074624

Transformation of tenofovir into stable ProTide nanocrystals with long-acting pharmacokinetic profiles

Ejemplares similares